Dr. Nicholas P. Marsico is an ophthalmologist in Los Angeles, California and is affiliated with multiple hospitals in the area, including PIH Health Good Samaritan Hospital and Torrance Memorial Medical Center.
Medical Education
1992-1996
MEDICAL SCHOOL: Ohio State University College of Medicine, Columbus, OHDoctor of Medicine degree 1996
1988-1992
UNDERGRADUATE: Ohio State University, Columbus, OHBachelor of Science Degree, Biology Major, History Minor, 1992
Postgraduate Training and Fellowship Appointments
2000-2001
FELLOWSHIP: Corneal/External Disease & Refractive SurgeryThe Eye & Ear Institute, University of Pittsburgh, Pittsburgh, PA
1997-2000
RESIDENCY: Boston University, Boston, MAChief Resident 2000
1996-1997
INTERNSHIP: Mount Carmel Medical Center, Transitional Year internshipColumbus, OH
Professional Positions
2004 – now
East West Eye Institute, Inc. Los Angeles, CA
2002 – 2004
Eye Specialists, Inc. Circleville, OH
2001 – 2002
Carolina Eye Associates, PA Raleigh, NC
Honors & Awards
- Phi Beta Kappa
- Summa Cum Laude
- Liberal Arts Honors
- Ohio State University College of Medicine Landacre Day research award recipient
- Roessler Memorial Research Scholarship, Ohio State University College of Medicine 1993 and 1994
Professional & Academic Societies
- Diplomate American Board of Ophthalmology – Board Certified October 2001, Recertified October 2011
- Fellow of the American College of Surgeons
- American Academy of Ophthalmology
- American Society of Cataract and Refractive Surgery
- International Society of Refractive Surgery
- California Academy of Eye Physicians and Surgeons
- Los Angeles Society of Ophthalmology
HOSPITAL AFFILIATIONS
- St. Vincent Medical Center – 04/19/05 to present
- 2131 W. Third St., Los Angeles, CA 90057-0992
- Good Samaritan Hospital – 09/23/04 to present
- 1225 Wilshire Blvd. Los Angeles, CA 90017
- Community Hospital of Gardena – 09/13/04 to present
- 1246 West 155th St. Gardena, CA 90247
- Clinton Memorial Hospital – 8/03 to 7/04
- 610 West Main St. Wilmington, OH 45177
- Berger Hospital – 9/25/02 to 6/04
- 600 N. Pickaway St., Circleville, OH 43113
- Rex Hospital – 9/11/01 to 2/26/02
- 4420 Lake Boone Trail, Raleigh, NC 27607
- Raleigh Community Hospital – 9/13/01 to 2/26/02
- – 3400 Wake Forest Rd, Raleigh, NC 27609
Poster Presentations
- Alloderm Grafting in the Irradiated Socket. Poster. European Society of Oculoplastic and Reconstructive Surgery,
Istanbul Turkey, Sept. 1999
- Vascular Changes in Diabetic Retina – Modified trypsin-digestion technique. Poster. ARVO, Sarasota Florida, 1994
- Geographical Distribution of Diabetic Retinal Vascular Abnormalities. Poster. ARVO, Sarasota Florida, 1994
Teacher Affiliation
- Mount Carmel Medical Center, clinical ophthalmology instructor for internal medicine residents, June 2002 – June 2004
Interests
- Fitness
- Watersports
- Travel
Clinical Trials
October 2012 – Principal Investigator: GMA-LAS-12-023: A Multi-Center, Double-Masked, Randomized, Active-And-Placebo-Controlled Evaluation of the Efficacy of Action of Lastacaft (Alcaftadine 0.25%) Ophthalmic Solution Compared to Pataday and Placebo in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis
June 2012 – Prinicipal Investigator: OMS302-ILR-004: A Phase 3 Randomized, Double-Masked, Placebo-Controlled Study of the Pharmocokinetics of OMS302 and the Effect of OMS302 on Intraoperative Pupil Diameter and Early Postoperative Pain in Subjects Undergoing Intraocular Lens Replacement with Phacoemulsification
October 2011 – Principal Investigator: OMS302-ILR-003: A Phase 3 Randomized, Double-Masked, Placebo-Controlled Study of the Effect of OMS302 on Intraoperative Pupil Diameter and Early Postoperative Pain in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification
July 2011 – Principal Investigator: B & L 661: A Study to Evaluate the Safety and Efficacy of a New Silicone Hydrogel Contact Lens Design
June 2011 – Principal Investigator: B & L 637: A Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Multicenter, Exploratory Study Assessing the Safety and Efficacy of BOL-303242-X Ophthalmic Suspension in Dry Eye Syndrome
April 2011 – Principal Investigator: A Study to Evaluate the Safety and Efficacy of a Novel Contact Lens Used in Healthy, Normal Volunteers that Live in an Urban Environment.
November 2010 – Principal Investigator: B & L Study 685 / 10-100-0021: A Multi-Center, Randomized, Evaluation of the Efficacy of BOL-303242-X (Maprocorat) Ophthalmic Suspension, (0.3%, 2%, and 3%) Compared to Vehicle in a Modified Conjunctival Allergen Challenge (CAC)
November 2010 – Principal Investigator: OMS302 C09-001: “A Study of Phenylephrine HCl’s and Ketorolac Tromethamine’s Ability, Alone and in Combination, to Maintain Mydriasis and Relieve Pain and Inflammation in Subjects Undergoing Unilateral Cataract Extraction with Lens Replacement (CELR)”
September 2010 – Principal Investigator: FOV1101/CLIN/202//P: A Multi-Center, Randomized, Double-Masked Evaluation of the Efficacy of Co-Administration of FOV1101-00 (Cyclosporine 0.01% or 0.02%) and Prednisolone Acetate 0.12% (Pred Mild) Compared to its Components and Vehicle in Patients with Mild Ongoing Ocular Allergic Inflammation
May 2010 – Principal Investigator: Aciex Therapeutics 10-100-0005: A Multi-Center, Randomized, Double-Masked Evaluation of the Efficacy of Cetirizine 0.1% / Fluticasone 0.005% Ophthalmic Solution Compared to its Components and Vehicle in a Modified Conjunctival Allergen Challenge (CAC) Model During Pollen Season
April 2010 – Principal Investigator: B & L 572 / 07-003-21: A Multi-Center, Double-Masked, Randomized, Vehicle and Active Controlled Evaluation of the Onset and Duration of Action of Ketonaph (Ketotifen Fumarate 0.025%, Naphazoline HC1 0.05%) Ophthalmic Solution in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis
March 2009 – Principal Investigator: A Multi-Center, Randomized, Double-Masked Evaluation of the Efficacy of Co-Administration of FOV1101-00 (Cyclosporine 0.01% or 0.02%) and Prednisolone Acetate 0.12% (Pred Mild®) Compared to its Components and Vehicle in Patients with Mild Ongoing Ocular Allergic Inflammation.
June 2008 – Principal Investigator: A Study to Evaluate the Clinical Performance of a Novel Multi-Purpose Solution.
January 2008 – Sub Investigator: Multi Center, Double Masked, Placebo Controlled, Evaluation of the Onset and Duration of Action of Two Concentrations of Bepotastine Besilate Ophthalmic Solution in the Conjunctival Allergen Challenge
November 2007 – Sub Investigator: Multi – Center, randomized, Double Masked, Placebo-Controlled, Parallel-Group Study Evaluating the Safety of a Novel Contact Lens Used Daily in Healthy, Normal Volunteers.
August 2007 – Sub Investigator: The efficacy, safety and tolerability of travoprost bak free 0.0004% (Travatan Z) compared to prior treatment with Latanoprost 0.0005%) in patients of Japanese origin.
May 2006 – Sub Investigator: Multi-Centered Evaluation of the Efficacy and Clinical Performance of the Duration of Action of Patanol Ophthalmic Solution vs. Livostin Ophthalmic Suspension Using the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis in Japanese Subjects.
February 2006 – Principal Investigator: A study to evaluate the clnical and microbial eficacy of 0.6% ISV-403 compared to Vigamox in the treatment of bacterial conjunctivitis.
